Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry.

Glecaprevir/pibrentasvir is a pangenotypic direct‐acting antiviral regimen approved for treating chronic hepatitis C virus. Real‐world use of protease‐inhibitor–containing regimens requires further evaluation in patients with cirrhosis. We evaluated the real‐world safety and effectiveness of glecaprevir/pibrentasvir in patients with cirrhosis from the German Hepatitis C‐Registry who initiated treatment between 2 August 2017 and 30 June 2019. Overall, 131 patients received 12‐week (on‐label) treatment and 51 received 8‐week (off‐label) treatment. No patient discontinued treatment due to adverse events. Four patients had serious adverse events; none were considered related to glecaprevir/pibrentasvir. Two patients had total bilirubin > 5 × upper limit of normal (ULN) during treatment. Three patients had alanine aminotransferase and three patients had aspartate aminotransferase > 3 × ULN. Rates of sustained virologic response were 100% (86/86) for 86 patients with available data. Glecaprevir/pibrentasvir treatment was well‐tolerated and highly effective in patients with chronic hepatitis C and cirrhosis in real‐world practice. [ABSTRACT FROM AUTHOR]
Copyright of Liver International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)